This led to discard the TaG3 FGFR3-mutated tumors (4% of FGFR3-mutated cases in the first data set) and the TaG1, G2 FGFR3-non-mutated tumors (9% of FGFR3-non-mutated cases in the first data set), as in these two subgroups the FGFR3 mutation was likely not the correct parameter for classifying a tumor in one of the two pathways (see paragraph on “Model of bladder cancer pathogenesis used in this study” in the Results section). This evidence concerns the gene FGFR3 and neoplasm.